Evidence map›Paper›PMID 40528062›Full record

ArticleBiochemical genetics2026

Predicting Risk of Lymph Node Metastasis in Papillary Thyroid Cancer Using miRNAs and Clinicopathological Features.

Penbe Gul Ergun, Cagatay Aydogan, Ayse Begum Ceviz, Gonca Candan, Sebnem Batur, Hulya Yilmaz Aydogan, Oguz Ozturk, Tulin Ozturk

Abstract read
PubMed Publisher
In one paragraph

Article in Biochemical genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Penbe Gul ErgunDepartment of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Fatih, 34096, Istanbul, Turkey.ORCID http://orcid.org/0009-0003-5904-1368
Cagatay AydoganDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-7520-070X
Ayse Begum CevizDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-3635-8421
Gonca CandanDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-9652-4332
Sebnem BaturDepartment of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Fatih, 34096, Istanbul, Turkey.ORCID http://orcid.org/0000-0001-6577-8970
Hulya Yilmaz AydoganDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-8837-6664
Oguz OzturkDepartment of Molecular Medicine, Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.ORCID http://orcid.org/0000-0002-2439-9269
Tulin OzturkDepartment of Pathology, Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa, Fatih, 34096, Istanbul, Turkey. drozturk@iuc.edu.tr.ORCID http://orcid.org/0000-0001-6910-1131

Funding

Scientific Projects Coordination Unit, Istanbul University-Cerrahpasa TTU-2019-33603
6 · The paper itself

Abstract

This study investigates potential prognostic values in models created with clinicopathological features and expression profiles of miRNAs known for their critical roles in papillary thyroid carcinoma (PTC) for lymph node metastasis (LNM) in PTC cases. Forty-seven lymph node-metastatic PTC patients and 46 non-metastatic patients were included. Using RT-PCR, miR-21, miR-146b, miR-221, and miR-222 expression was analyzed in carcinoma tissues and metastatic lymph nodes of the same PTC patients and carcinoma tissues of non-metastatic PTC patients. MiR-146b (p < 0.001) and miR-221 (p = 0.009) were overexpressed in metastatic PTCs compared to non-metastatic PTCs. The miRNA expression profiles were similar in the lymph nodes and primary cancer of metastatic PTCs. In the presence of larger tumors (> 1 cm) in metastatic PTCs, miR-146b and miR221 were overexpressed in the tumor tissue (p = 0.036), while miR-222 was overexpressed in metastatic lymph nodes (p = 0.035). miR-146b was also upregulated in lack of peritumoral lymphocyte infiltration (p = 0.006). In conclusion, our findings suggest that the overexpression of miR-146b and miR-221 in PTC tissues may be associated with lymph node metastasis and a poorer prognosis. Furthermore, the presence of larger tumors and increased levels of intratumoral fibrosis in non-metastatic PTC patients could indicate a poor prognosis.

Indexed as

CarcinomaCarcinoma, PapillaryMicroRNAsThyroid NeoplasmsAdultAgedBiomarkers, TumorFemaleGene Expression Regulation, NeoplasticHumansLymphatic MetastasisMaleMiddle AgedPrognosisThyroid Cancer, PapillaryBiomarkers, TumorMicroRNAsLymph node metastasisMi-RNAPapillary carcinomaPrognosisThyroid

Identifiers

PMID40528062

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.